How to manage coagulopathies in critically ill patients

被引：0

作者：

Julie Helms

Toshiaki Iba

Jean Marie Connors

Satoshi Gando

Marcel Levi

Ferhat Meziani

Jerrold H. Levy

机构：

[1] Université de Strasbourg (UNISTRA),Department of Emergency and Disaster Medicine

[2] Faculté de Médecine,Hematology Division

[3] Hôpitaux Universitaires de Strasbourg,Department of Acute and Critical Care Medicine

[4] Service de Médecine Intensive-Réanimation,Division of Acute and Critical Care Medicine, Department of Anesthesiology and Critical Care Medicine

[5] Nouvel Hôpital Civil,Department of Vascular Medicine

[6] INSERM (French National Institute of Health and Medical Research),Department of Medicine

[7] UMR 1260,Department of Anesthesiology, Critical Care, and Surgery

[8] Regenerative Nanomedicine (RNM),undefined

[9] FMTS,undefined

[10] Juntendo University Graduate School of Medicine,undefined

[11] Brigham and Women’s Hospital,undefined

[12] Harvard Medical School,undefined

[13] Sapporo Higashi Tokushukai Hospital,undefined

[14] Hokkaido University Faculty of Medicine,undefined

[15] Amsterdam University Medical Centers,undefined

[16] University College London Hospitals NHS Foundation Trust,undefined

[17] and Cardio-Metabolic Programme-NIHR UCLH/UCL BRC London,undefined

[18] Duke University School of Medicine,undefined

来源：

Intensive Care Medicine | 2023年 / 49卷

关键词：

Disseminated intravascular coagulation; Coagulopathy; Sepsis; Trauma; Hematological disease; Critical care;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Coagulopathy is a severe and frequent complication in critically ill patients, for which the pathogenesis and presentation may be variable depending on the underlying disease. Based on the dominant clinical phenotype, the current review differentiates between hemorrhagic coagulopathies, characterized by a hypocoagulable and hyperfibrinolysis state, and thrombotic coagulopathies with a systemic prothrombotic and antifibrinolytic phenotype. We discuss the differences in pathogenesis and treatment of the common coagulopathies.

引用

页码：273 / 290

页数：17

共 50 条

[31] How should ethical committees promote research in critically ill patients?
Caironi, Pietro
Fumagalli, Roberto
Tognoni, Gianni
MINERVA ANESTESIOLOGICA, 2016, 82 (04) : 389 - 391
[32] How natural light affects critically ill patients with subarachnoid hemorrhage
Hongliang Zhang
Jiang Wu
Critical Care, 15 (3):
[33] Lumbar puncture in critically ill patients: How likely is it to change management?
Khasawneh, FA
Mohamad, T
Moughrabieh, MK
Soubani, A
CRITICAL CARE MEDICINE, 2005, 33 (12) : A102 - A102
[34] How should we deal with muscle weakness in critically ill patients?
Dincer, H. Erhan
CRITICAL CARE MEDICINE, 2009, 37 (09) : 2648 - 2649
[35] Early mobilisation of critically ill patients: How soon is soon enough?
Lathyris, Dimitrios
INTENSIVE AND CRITICAL CARE NURSING, 2024, 82
[36] Adrenal function in critically ill patients: How to test? When to treat?
Hamrahian, A
CLEVELAND CLINIC JOURNAL OF MEDICINE, 2005, 72 (05) : 427 - 432
[37] How do Europeans transfuse critically ill trauma/surgical patients
De Backer, D
SHOCK, 2004, 21 : 120 - 120
[38] What, why and how to monitor blood glucose in critically ill patients
Juneja, Deven
Deepak, Desh
Nasa, Prashant
WORLD JOURNAL OF DIABETES, 2023, 14 (05) : 528 - 538
[39] High volume hemofiltration in critically ill patients: Why, when and how?
Tetta, C
Bellomo, R
Kellum, J
Ricci, Z
Pohlmeier, R
Passlick-Deetjen, D
Ronco, C
SEPSIS, KIDNEY AND MULTIPLE ORGAN DYSFUNCTION, 2004, 144 : 362 - 375
[40] Cognitive impairment in critically ill patients and former critically ill patients: A concept analysis
Hanifa, Ann Louise Bodker
Svenningsen, Helle
Moller, Annemaia Nadine
Dreyer, Pia
Holm, Anna
AUSTRALIAN CRITICAL CARE, 2024, 37 (01) : 166 - 175

← 1 2 3 4 5 →